Arch Oncology
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2000 Sierra Point Pkwy Fl 700, Brisbane,...Phone Number
(415) 671-4035Website
www.archoncology.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Arch Oncology
Arch Oncology, Inc. was founded in 2006 out of Brisbane, California, they are a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class biologic therapies for the treatment of patients with solid tumors and hematologic malignancies. AO-176, the Company's next-generation anti-CD47 antibody, is highly differentiated, with the potential for an improved safety and efficacy profile relative to other agents in this class. AO-176 is in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and with hematologic malignancies, both as monotherapy and in combination with standard therapies. In addition, the Company is advancing a pipeline of antibody programs for the treatment of cancer.Explore more
Arch Oncology Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arch Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Arch Oncology is spiking on competitors!
Arch Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Arch Oncology had a recent Job posting/layoffs
Earning: See what the market has to say on Arch Oncology recently announced quarterly report
Product Launch: Get notified when Arch Oncology launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Arch Oncology has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Arch Oncology has new funding data
Congratulate Masked Content for being promoted to Masked Content at Arch Oncology
Recommended Actions
Reach out to Masked Content who joined Arch Oncology as Masked Content
Find 2 more new buyers
Compare Similar Companies to Arch Oncology
Compare insights from companies similar to Arch Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Arch Oncology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Arch Oncology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Arch Oncology.
Arch Oncology financials insights
Gather financial insights about Arch Oncology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$86M
2019
Series B
$50M
2020
Debt
$350K
2021
Series C
$105M
Arch Oncology Tech Stack
A closer look at the technologies used by Arch Oncology
Most Recent Scoops
Layoffs
Pain Point
Pain Point, Layoffs
Left Company
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Arch Oncology has announced that Ronald Krasnow, Chief Operating Officer, has left the company to join T-Knife Therapeutics as General Counsel.
Executive Move
Executive Moves
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Arch Oncology
Sign Up For FreeTo access detailed company insights
Arch Oncology, Inc. was founded in 2006 out of Brisbane, California, they are a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class biologic therapies for the treatment of patients with solid tumors and hematologic malignancies. AO-176, the Company's next-generation anti-CD47 an... Read More
